elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q58407688-51C11E46-F3B0-4826-83C7-6AD7D97C96F3
Q58407688-51C11E46-F3B0-4826-83C7-6AD7D97C96F3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q58407688-51C11E46-F3B0-4826-83C7-6AD7D97C96F3
Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma
P921
Q58407688-51C11E46-F3B0-4826-83C7-6AD7D97C96F3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q58407688-51C11E46-F3B0-4826-83C7-6AD7D97C96F3
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
949f69c6011ada9f7873d7397cefb64055fdc2fa
P921
cancer immunotherapy